A database study of clinical and economic burden of invasive meningococcal disease in France

Liping Huang1, Stéphane Fievez2, Mélanie Goguillot3

  • 1Pfizer, Collegeville, Pennsylvania, United States of America.

Plos One
|April 29, 2022
PubMed
Abstract

Insights

Invasive meningococcal disease (IMD) poses severe health risks and high costs. Sequelae, combined meningitis and meningococcaemia, and older age significantly increase hospitalization expenses.

Area of Science:

  • Epidemiology
  • Public Health
  • Health Economics

Background:

  • Invasive meningococcal disease (IMD) is a severe, life-threatening infection.
  • IMD is associated with significant morbidity and mortality.
  • Understanding the economic burden of IMD is crucial for public health planning.

Purpose of the Study:

  • To examine the clinical characteristics of IMD patients in France.
  • To assess hospital-based healthcare resource utilization (HRU) and costs associated with IMD.
  • To identify factors influencing IMD-related healthcare costs.

Main Methods:

  • Retrospective analysis of 1,344 patients diagnosed with IMD between 2014-2016 using the French hospital discharge database (PMSI).
  • Description of demographics, clinical outcomes, and HRU during the index hospitalization.
  • Examination of HRU and costs during a 1-year follow-up period using a generalized linear model.

Main Results:

  • The case fatality rate during index hospitalization was 6%, with 15% of patients experiencing sequelae.
  • Median length of stay was 9 days, and median index hospitalization cost was 8,045€.
  • Higher costs were associated with sequelae, combined meningitis and meningococcaemia, and patients aged 25 years and older.

Conclusions:

  • IMD is unpredictable and affects all age groups, highlighting its broad impact.
  • The study underscores the significant health and economic burdens imposed by IMD.
  • Findings emphasize the critical importance of IMD prevention, particularly through vaccination.